Seer(US:SEER)2026-02-26 21:08Revenue Growth - Revenue for Q4 2025 was $4.2 million, a 5% increase from $4.0 million in Q4 2024, driven by higher product revenue [4]. - Full year 2025 revenue reached $16.6 million, a 17% increase from $14.2 million in 2024, attributed to increased product sales and service revenue [8]. - Seer expects full year 2026 revenue to be in the range of $16 million to $18 million, indicating approximately 3% growth at the midpoint over 2025 [11]. Installed Base - The installed base grew to 82 instruments, representing a 67% year-over-year increase, with 33 instruments installed during 2025 [7]. Profitability and Loss - Gross profit for Q4 2025 was $2.2 million, with a gross margin of 52% [5]. - Net loss for Q4 2025 was $16.0 million, an improvement from a net loss of $21.7 million in Q4 2024 [6]. - Full year 2025 net loss was $73.6 million, compared to a net loss of $86.6 million in 2024 [10]. Operating Expenses - Operating expenses decreased by 23% to $19.6 million in Q4 2025, down from $25.5 million in Q4 2024 [5]. Financial Position - Cash, cash equivalents, and investments totaled approximately $240.6 million as of December 31, 2025 [10]. Research and Development - Significant customer studies published in Nature and Nature Genetics demonstrated the capabilities of the Proteograph for biomarker discovery [7].